RXi Acquires Apthera, Reorganizes To Support Late-Stage Breast Cancer Product

Formerly focused on preclinical RNA interference compounds, the company installs a new CEO and takes possession of a cancer immunotherapy, the latest move away from RNAi by companies big and small.